Ziftomenib Maintenance Post Allo-HCT
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMassachusetts General Hospital
About this trial
The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT.
The name of the study drug involved in this study is:
• Ziftomenib
Eligibility criteria
Qualifiers
18 years or older.
Pathologically confirmed diagnosis of acute myeloid leukemia (AML).
Complete remission (CR) or complete remission with incomplete count recovery (CRi) at screening.
no circulating blasts in peripheral blood and <5% blasts in bone marrow
Disqualifiers
History of other malignancy(ies) unless
the participant has been disease-free for at least 2 years and is deemed by the investigator to be at low risk of recurrence of that malignancy, or
the cancer has been deemed indolent with no progression over the last 2 years, and deemed by the investigator to be at low risk for further progression during the course of study and follow-up
the only prior malignancy was cervical cancer in situ and/or basal cell or squamous cell carcinoma of the skin
Trial design
Treatments tested in this trial
- Ziftomenib
Treatment groups
22 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov